Vimarsana
Biggest News Aggregation in the World

Mark Litton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Litton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Litton Today - Breaking & Trending Today

How Sen. Sherrod Brown got involved in CD 92.9's Ohio FM radio exodus - Vimarsana News

How Sen. Sherrod Brown got involved in CD 92.9's Ohio FM radio exodus

As CD 92.9 FM's final hours broadcasting as a terrestrial radio station ticked down, one of Ohio's U.S. senators tried to intervene before it lost access to the airwaves.

Source: nbc4i.com
Filing hints dormant Columbus radio brand could take over CD 92.9 FM's frequency - Vimarsana News

Filing hints dormant Columbus radio brand could take over CD 92.9 FM's frequency

View a previous report in the video player above. COLUMBUS, Ohio (WCMH) — A document filed with the Federal Communications Commission sheds light on what may happen when a Columbus alternative radio station is scheduled to go off the air at the end of January. ICS Communications — one of three parties in failed negotiations […]

Source: yahoo.com
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update - Vimarsana News

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024  Plans to...

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease Seite 1 - Vimarsana News

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease Seite 1

03.01.2024 - Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach ... Seite 1

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease -January 03, 2024 at 07:02 am EST - Vimarsana News

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease -January 03, 2024 at 07:02 am EST

Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of...